ff_relativeren schreef op 20 december 2019 01:23:
4. Hospira € 24 miljoen lening is gekoppeld aan het Theralux Platform, mijlpaalbetalingen, en het betalen van royalties (naast rentebetaling) :
bron : www.kiadis.com/wp-content/uploads/201...
In December 2011, the Company entered into an agreement with Hospira Inc. for which an amount of USD24.5 million had been judged as a loan. The loan bears a contractual interest rate of 1.5% per annum and the conditional payment obligations regarding this loan are as follows:
4. a milestone payment of USD3 million upon the earlier of (i) the execution of a sub-license on the Theralux platform, or (ii) the first commercial sale of a product derived from the Theralux platform; and
5. a 5% royalty on worldwide net sales of products derived from the Theralux product platform until the loan amount has been fully paid.
The carrying amount of this loan as at June 30, 2018, has been adjusted by an amount of EUR42 thousand to reflect changes in the (estimated) underlying future cash flows. This amount has been charged to the income statement (see also Note 16). Hoe eerder Kiadis Pharma deze contracten kan afkopen, hoe beter het is voor de (toekomstige) bewegingsvrijheid van Kiadis. (1e Kreos lening 15 miljoen ; 2e Kreos lening 5 miljoen ; Hospira lening 24,5 miljoen)